According to the research report, the global market for Transarterial Chemoembolization (TACE) should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China Transarterial Chemoembolization (TACE) market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029. The United States Transarterial Chemoembolization (TACE) market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By segment, Hospitals grew percent to account for percent of the total market sales, and Clinics grew percent.
Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.
This report studies and analyses global Transarterial Chemoembolization (TACE) status and future trends, to help determine the Transarterial Chemoembolization (TACE) market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Transarterial Chemoembolization (TACE), and provides market size (US$ million) and Year-over-Year growth, considering 2022 as the base year.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
To assess the competitive environment within the market including supplier revenue, market share, and company profiles.
Highlights
(1) Global Transarterial Chemoembolization (TACE) market size, history data 2018-2023, and forecast data 2024-2029, (US$ million)
(2) Global Transarterial Chemoembolization (TACE) by company, revenue, market share and industry ranking 2018-2023, (US$ million)
(3) China Transarterial Chemoembolization (TACE) by company, revenue, market share and industry ranking 2018-2023, (US$ million)
(4) Global Transarterial Chemoembolization (TACE) key consuming regions, consumption value and demand structure
(5) Transarterial Chemoembolization (TACE) industry chains, upstream, midstream and downstream
Market segment by players, this report covers
Questex
Siemens Healthcare GmbH
Bellicum Pharmaceuticals Inc.
Boston Scientific
Cook Group
Hikma Pharmaceuticals
Nippon Kayaku
Novartis AG
Pfizer Inc.
Spectrum Pharmaceutical
Roche Holding AG
Celgene
Bayer AG
Merck & Co., Inc.
SingHealth
Market segment by Type, covers
Chemotherapeutic Agents
Radio Therapeutic Agents
Drug-eluting Particles
Others
Market segment by Application, can be divided into
Hospitals
Clinics
Cancer Research Centers
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Transarterial Chemoembolization (TACE) product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Transarterial Chemoembolization (TACE) market share and ranking of major manufacturers, revenue, 2018-2023
Chapter 3: China Transarterial Chemoembolization (TACE) market share and ranking of major manufacturers, revenue, 2018-2023
Chapter 4: Transarterial Chemoembolization (TACE) industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2018-2029
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2018-2029
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2018-2029
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2018-2029
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions
1 Market Overview
1.1 Transarterial Chemoembolization (TACE) Definition
1.2 Global Transarterial Chemoembolization (TACE) Market Size and Forecast
1.3 China Transarterial Chemoembolization (TACE) Market Size and Forecast
1.4 China Percentage in Global Market
1.5 Transarterial Chemoembolization (TACE) Market Size: China VS Global Growth Rate, 2018-2029
1.6 Transarterial Chemoembolization (TACE) Market Dynamics
1.6.1 Transarterial Chemoembolization (TACE) Market Drivers
1.6.2 Transarterial Chemoembolization (TACE) Market Restraints
1.6.3 Transarterial Chemoembolization (TACE) Industry Trends
1.6.4 Transarterial Chemoembolization (TACE) Industry Policy
2 Global Leading Players and Market Share
2.1 By Revenue of Transarterial Chemoembolization (TACE), Global Market Share by Company, 2018-2023
2.2 Global Transarterial Chemoembolization (TACE) Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Transarterial Chemoembolization (TACE) Concentration Ratio
2.4 Global Transarterial Chemoembolization (TACE) Mergers & Acquisitions, Expansion Plans
2.5 Global Transarterial Chemoembolization (TACE) Major Companies Product Type
2.6 Head Office and Transarterial Chemoembolization (TACE) Production Site of Key Manufacturer
3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Transarterial Chemoembolization (TACE), China Market Share by Company, 2018-2023
3.2 China Transarterial Chemoembolization (TACE) Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Industry Chain Analysis
4.1 Transarterial Chemoembolization (TACE) Industry Chain
4.2 Transarterial Chemoembolization (TACE) Upstream Analysis
4.2.1 Transarterial Chemoembolization (TACE) Core Raw Materials
4.2.2 Main Manufacturers of Transarterial Chemoembolization (TACE) Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Transarterial Chemoembolization (TACE) Production Mode
4.6 Transarterial Chemoembolization (TACE) Procurement Model
4.7 Transarterial Chemoembolization (TACE) Industry Sales Model and Sales Channels
4.7.1 Transarterial Chemoembolization (TACE) Sales Model
4.7.2 Transarterial Chemoembolization (TACE) Typical Distributors
5 Sights by Type
5.1 Transarterial Chemoembolization (TACE) Classification
5.1.1 Chemotherapeutic Agents
5.1.2 Radio Therapeutic Agents
5.1.3 Drug-eluting Particles
5.1.4 Others
5.2 By Type, Global Transarterial Chemoembolization (TACE) Consumption Value & CAGR, 2018 VS 2022 VS 2029
5.3 By Type, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029
6 Sights by Application
6.1 Transarterial Chemoembolization (TACE) Segment by Application
6.1.1 Hospitals
6.1.2 Clinics
6.1.3 Cancer Research Centers
6.2 By Application, Global Transarterial Chemoembolization (TACE) Consumption Value & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018 VS 2022 VS 2029
7.2 By Region, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029
7.3 North America
7.3.1 North America Transarterial Chemoembolization (TACE) & Forecasts, 2018-2029
7.3.2 By Country, North America Transarterial Chemoembolization (TACE) Market Size Market Share
7.4 Europe
7.4.1 Europe Transarterial Chemoembolization (TACE) Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Transarterial Chemoembolization (TACE) Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Transarterial Chemoembolization (TACE) Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Transarterial Chemoembolization (TACE) Market Size Market Share
7.6 South America
7.6.1 South America Transarterial Chemoembolization (TACE) Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Transarterial Chemoembolization (TACE) Market Size Market Share
7.7 Middle East & Africa
8 Sales Sights by Country Level
8.1 By Country, Global Transarterial Chemoembolization (TACE) Market Size & CAGR, 2018 VS 2022 VS 2029
8.2 By Country, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029
8.3 U.S.
8.3.1 U.S. Transarterial Chemoembolization (TACE) Market Size, 2018-2029
8.3.2 By Type, U.S. Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.3.3 By Application, U.S. Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Transarterial Chemoembolization (TACE) Market Size, 2018-2029
8.4.2 By Type, Europe Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.4.3 By Application, Europe Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.5 China
8.5.1 China Transarterial Chemoembolization (TACE) Market Size, 2018-2029
8.5.2 By Type, China Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.5.3 By Application, China Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Transarterial Chemoembolization (TACE) Market Size, 2018-2029
8.6.2 By Type, Japan Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.6.3 By Application, Japan Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Transarterial Chemoembolization (TACE) Market Size, 2018-2029
8.7.2 By Type, South Korea Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.7.3 By Application, South Korea Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Transarterial Chemoembolization (TACE) Market Size, 2018-2029
8.8.2 By Type, Southeast Asia Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.8.3 By Application, Southeast Asia Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.9 India
8.9.1 India Transarterial Chemoembolization (TACE) Market Size, 2018-2029
8.9.2 By Type, India Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.9.3 By Application, India Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.10 Middle East & Africa
8.10.1 Middle East & Africa Transarterial Chemoembolization (TACE) Market Size, 2018-2029
8.10.2 By Type, Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
8.10.3 By Application, Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
9 Company Profile
9.1 Questex
9.1.1 Questex Company Information, Head Office, Market Area and Industry Position
9.1.2 Questex Company Profile and Main Business
9.1.3 Questex Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.1.4 Questex Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.1.5 Questex Recent Developments
9.2 Siemens Healthcare GmbH
9.2.1 Siemens Healthcare GmbH Company Information, Head Office, Market Area and Industry Position
9.2.2 Siemens Healthcare GmbH Company Profile and Main Business
9.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.2.4 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.2.5 Siemens Healthcare GmbH Recent Developments
9.3 Bellicum Pharmaceuticals Inc.
9.3.1 Bellicum Pharmaceuticals Inc. Company Information, Head Office, Market Area and Industry Position
9.3.2 Bellicum Pharmaceuticals Inc. Company Profile and Main Business
9.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.3.4 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.3.5 Bellicum Pharmaceuticals Inc. Recent Developments
9.4 Boston Scientific
9.4.1 Boston Scientific Company Information, Head Office, Market Area and Industry Position
9.4.2 Boston Scientific Company Profile and Main Business
9.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.4.4 Boston Scientific Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.4.5 Boston Scientific Recent Developments
9.5 Cook Group
9.5.1 Cook Group Company Information, Head Office, Market Area and Industry Position
9.5.2 Cook Group Company Profile and Main Business
9.5.3 Cook Group Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.5.4 Cook Group Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.5.5 Cook Group Recent Developments
9.6 Hikma Pharmaceuticals
9.6.1 Hikma Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
9.6.2 Hikma Pharmaceuticals Company Profile and Main Business
9.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.6.4 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.6.5 Hikma Pharmaceuticals Recent Developments
9.7 Nippon Kayaku
9.7.1 Nippon Kayaku Company Information, Head Office, Market Area and Industry Position
9.7.2 Nippon Kayaku Company Profile and Main Business
9.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.7.4 Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.7.5 Nippon Kayaku Recent Developments
9.8 Novartis AG
9.8.1 Novartis AG Company Information, Head Office, Market Area and Industry Position
9.8.2 Novartis AG Company Profile and Main Business
9.8.3 Novartis AG Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.8.4 Novartis AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.8.5 Novartis AG Recent Developments
9.9 Pfizer Inc.
9.9.1 Pfizer Inc. Company Information, Head Office, Market Area and Industry Position
9.9.2 Pfizer Inc. Company Profile and Main Business
9.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.9.4 Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.9.5 Pfizer Inc. Recent Developments
9.10 Spectrum Pharmaceutical
9.10.1 Spectrum Pharmaceutical Company Information, Head Office, Market Area and Industry Position
9.10.2 Spectrum Pharmaceutical Company Profile and Main Business
9.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.10.4 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.10.5 Spectrum Pharmaceutical Recent Developments
9.11 Roche Holding AG
9.11.1 Roche Holding AG Company Information, Head Office, Market Area and Industry Position
9.11.2 Roche Holding AG Company Profile and Main Business
9.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.11.4 Roche Holding AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.11.5 Roche Holding AG Recent Developments
9.12 Celgene
9.12.1 Celgene Company Information, Head Office, Market Area and Industry Position
9.12.2 Celgene Company Profile and Main Business
9.12.3 Celgene Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.12.4 Celgene Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.12.5 Celgene Recent Developments
9.13 Bayer AG
9.13.1 Bayer AG Company Information, Head Office, Market Area and Industry Position
9.13.2 Bayer AG Company Profile and Main Business
9.13.3 Bayer AG Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.13.4 Bayer AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.13.5 Bayer AG Recent Developments
9.14 Merck & Co., Inc.
9.14.1 Merck & Co., Inc. Company Information, Head Office, Market Area and Industry Position
9.14.2 Merck & Co., Inc. Company Profile and Main Business
9.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.14.4 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.14.5 Merck & Co., Inc. Recent Developments
9.15 SingHealth
9.15.1 SingHealth Company Information, Head Office, Market Area and Industry Position
9.15.2 SingHealth Company Profile and Main Business
9.15.3 SingHealth Transarterial Chemoembolization (TACE) Models, Specifications and Application
9.15.4 SingHealth Transarterial Chemoembolization (TACE) Revenue and Gross Margin, 2018-2023
9.15.5 SingHealth Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Table 1. Transarterial Chemoembolization (TACE) Consumption Value & CAGR: China VS Global, 2018-2029, US$ Million
Table 2. Transarterial Chemoembolization (TACE) Market Restraints
Table 3. Transarterial Chemoembolization (TACE) Market Trends
Table 4. Transarterial Chemoembolization (TACE) Industry Policy
Table 5. Global Transarterial Chemoembolization (TACE) Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022
Table 6. Global Transarterial Chemoembolization (TACE) Revenue Share by Company, 2018-2023, Ranked by Data of 2022
Table 7. Global Transarterial Chemoembolization (TACE) Manufacturers Market Concentration Ratio (CR3 and HHI)
Table 8. Global Transarterial Chemoembolization (TACE) Mergers & Acquisitions, Expansion Plans
Table 9. Global Transarterial Chemoembolization (TACE) Major Companies Product Type
Table 10. Head Office and Area Served of Key Players
Table 11. China Transarterial Chemoembolization (TACE) Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022
Table 12. China Transarterial Chemoembolization (TACE) Revenue Market Share by Company, 2018-2023
Table 13. Global Key Players of Transarterial Chemoembolization (TACE) Upstream (Raw Materials)
Table 14. Global Transarterial Chemoembolization (TACE) Typical Customers
Table 15. Transarterial Chemoembolization (TACE) Typical Distributors
Table 16. By Type, Global Transarterial Chemoembolization (TACE) Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 17. By Application, Global Transarterial Chemoembolization (TACE) Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 18. By Region, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018 VS 2022 VS 2029, US$ Million
Table 19. By Region, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Table 20. By Country, Global Transarterial Chemoembolization (TACE) Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 21. By Country, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Table 22. By Country, Global Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2018-2029
Table 23. Questex Company Information, Head Office, Market Area and Industry Position
Table 24. Questex Company Profile and Main Business
Table 25. Questex Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 26. Questex Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 27. Questex Recent Developments
Table 28. Siemens Healthcare GmbH Company Information, Head Office, Market Area and Industry Position
Table 29. Siemens Healthcare GmbH Company Profile and Main Business
Table 30. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 31. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 32. Siemens Healthcare GmbH Recent Developments
Table 33. Bellicum Pharmaceuticals Inc. Company Information, Head Office, Market Area and Industry Position
Table 34. Bellicum Pharmaceuticals Inc. Company Profile and Main Business
Table 35. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 36. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 37. Bellicum Pharmaceuticals Inc. Recent Developments
Table 38. Boston Scientific Company Information, Head Office, Market Area and Industry Position
Table 39. Boston Scientific Company Profile and Main Business
Table 40. Boston Scientific Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 41. Boston Scientific Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 42. Boston Scientific Recent Developments
Table 43. Cook Group Company Information, Head Office, Market Area and Industry Position
Table 44. Cook Group Company Profile and Main Business
Table 45. Cook Group Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 46. Cook Group Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 47. Cook Group Recent Developments
Table 48. Hikma Pharmaceuticals Company Information, Head Office, Market Area and Industry Position
Table 49. Hikma Pharmaceuticals Company Profile and Main Business
Table 50. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 51. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 52. Hikma Pharmaceuticals Recent Developments
Table 53. Nippon Kayaku Company Information, Head Office, Market Area and Industry Position
Table 54. Nippon Kayaku Company Profile and Main Business
Table 55. Nippon Kayaku Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 56. Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 57. Nippon Kayaku Recent Developments
Table 58. Novartis AG Company Information, Head Office, Market Area and Industry Position
Table 59. Novartis AG Company Profile and Main Business
Table 60. Novartis AG Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 61. Novartis AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 62. Novartis AG Recent Developments
Table 63. Pfizer Inc. Company Information, Head Office, Market Area and Industry Position
Table 64. Pfizer Inc. Company Profile and Main Business
Table 65. Pfizer Inc. Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 66. Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 67. Pfizer Inc. Recent Developments
Table 68. Spectrum Pharmaceutical Company Information, Head Office, Market Area and Industry Position
Table 69. Spectrum Pharmaceutical Company Profile and Main Business
Table 70. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 71. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 72. Spectrum Pharmaceutical Recent Developments
Table 73. Roche Holding AG Company Information, Head Office, Market Area and Industry Position
Table 74. Roche Holding AG Company Profile and Main Business
Table 75. Roche Holding AG Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 76. Roche Holding AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 77. Roche Holding AG Recent Developments
Table 78. Celgene Company Information, Head Office, Market Area and Industry Position
Table 79. Celgene Company Profile and Main Business
Table 80. Celgene Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 81. Celgene Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 82. Celgene Recent Developments
Table 83. Bayer AG Company Information, Head Office, Market Area and Industry Position
Table 84. Bayer AG Company Profile and Main Business
Table 85. Bayer AG Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 86. Bayer AG Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 87. Bayer AG Recent Developments
Table 88. Merck & Co., Inc. Company Information, Head Office, Market Area and Industry Position
Table 89. Merck & Co., Inc. Company Profile and Main Business
Table 90. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 91. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 92. Merck & Co., Inc. Recent Developments
Table 93. SingHealth Company Information, Head Office, Market Area and Industry Position
Table 94. SingHealth Company Profile and Main Business
Table 95. SingHealth Transarterial Chemoembolization (TACE) Models, Specifications, and Application
Table 96. SingHealth Transarterial Chemoembolization (TACE) Revenue and Gross Margin, US$ Million, 2018-2023
Table 97. SingHealth Recent Developments
List of Figures
Figure 1. Transarterial Chemoembolization (TACE) Picture
Figure 2. Global Transarterial Chemoembolization (TACE) Consumption Value, (US$ million) & (2018-2029)
Figure 3. China Transarterial Chemoembolization (TACE) Consumption Value, (US$ million) & (2018-2029)
Figure 4. By Consumption Value, China Transarterial Chemoembolization (TACE) Market Share of Global, 2018-2029
Figure 5. Global Transarterial Chemoembolization (TACE) Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2022
Figure 6. China Transarterial Chemoembolization (TACE) Key Participants, Market Share, 2022
Figure 7. Transarterial Chemoembolization (TACE) Industry Chain
Figure 8. Transarterial Chemoembolization (TACE) Procurement Model
Figure 9. Transarterial Chemoembolization (TACE) Sales Model
Figure 10. Transarterial Chemoembolization (TACE) Sales Channels, Direct Sales, and Distribution
Figure 11. Chemotherapeutic Agents
Figure 12. Radio Therapeutic Agents
Figure 13. Drug-eluting Particles
Figure 14. Others
Figure 15. By Type, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 16. By Type, Global Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2018-2029
Figure 17. Hospitals
Figure 18. Clinics
Figure 19. Cancer Research Centers
Figure 20. By Application, Global Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 21. By Application, Global Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2018-2029
Figure 22. By Region, Global Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2018-2029
Figure 23. North America Transarterial Chemoembolization (TACE) Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 24. By Country, North America Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022
Figure 25. Europe Transarterial Chemoembolization (TACE) Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 26. By Country, Europe Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022
Figure 27. Asia Pacific Transarterial Chemoembolization (TACE) Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 28. By Country/Region, Asia Pacific Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022
Figure 29. South America Transarterial Chemoembolization (TACE) Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 30. By Country, South America Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022
Figure 31. Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 32. U.S. Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 33. By Type, U.S. Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 34. By Application, U.S. Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 35. Europe Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 36. By Type, Europe Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 37. By Application, Europe Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 38. China Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 39. By Type, China Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 40. By Application, China Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 41. Japan Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 42. By Type, Japan Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 43. By Application, Japan Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 44. South Korea Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 45. By Type, South Korea Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 46. By Application, South Korea Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 47. Southeast Asia Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 48. By Type, Southeast Asia Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 49. By Application, Southeast Asia Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 50. India Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 51. By Type, India Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 52. By Application, India Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 53. Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value, 2018-2029, US$ Million
Figure 54. By Type, Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 55. By Application, Middle East & Africa Transarterial Chemoembolization (TACE) Consumption Value Market Share, 2022 VS 2029
Figure 56. Research Methodology
Figure 57. Breakdown of Primary Interviews
Figure 58. Bottom-up and Top-down Approaches
Figure 59. Top-down Approaches
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
Historical Data (2015-2019) |
|
|
Influencing Factors |
|
|
Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
Market Size |
|
|
Market Position of Top Company |
|
|
Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
Primary Sources | Parameters | Key Data |
Market Segments(by Application, by Type) |
|
|
Total Market |
|
|